

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)



(10) International Publication Number
WO 2024/193253 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) *C12N 15/63* (2006.01)
A61P 35/00 (2006.01) *C12N 5/10* (2006.01)
C07K 14/55 (2006.01)

(21) International Application Number:

PCT/CN2024/076272

(22) International Filing Date:

06 February 2024 (06.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/082375
18 March 2023 (18.03.2023) CN
PCT/CN2023/120377
21 September 2023 (21.09.2023) CN

(71) Applicant: **XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.** [CN/CN]; Room 301, Building C29, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, China, Suzhou, Jiangsu 215127 (CN).

(72) Inventors: **ZHANG, Yifu**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, China, Daxing District, Beijing 102600 (CN). **LI, Zhuolin**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, China, Daxing District, Beijing 102600 (CN). **WANG, Nannan**; Room 301, Building C29, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, China, Suzhou, Jiangsu

215127 (CN). **SHEN, Yuelei**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, China, Daxing District, Beijing 102600 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-HER3/MUC1 ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: This disclosure relates to anti-HER3/MUC1 antibodies, and antibody drug conjugates derived therefrom, and the use thereof.

WO 2024/193253 A1